WO2008024408A3 - Pharmaceutical formulations of cannabinoids for application to the skin and method of use - Google Patents

Pharmaceutical formulations of cannabinoids for application to the skin and method of use Download PDF

Info

Publication number
WO2008024408A3
WO2008024408A3 PCT/US2007/018585 US2007018585W WO2008024408A3 WO 2008024408 A3 WO2008024408 A3 WO 2008024408A3 US 2007018585 W US2007018585 W US 2007018585W WO 2008024408 A3 WO2008024408 A3 WO 2008024408A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
application
cannabinoids
pharmaceutical formulations
cannabinoid
Prior art date
Application number
PCT/US2007/018585
Other languages
French (fr)
Other versions
WO2008024408A2 (en
Inventor
Najib Babul
Original Assignee
Theraquest Biosciences Inc
Najib Babul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraquest Biosciences Inc, Najib Babul filed Critical Theraquest Biosciences Inc
Publication of WO2008024408A2 publication Critical patent/WO2008024408A2/en
Publication of WO2008024408A3 publication Critical patent/WO2008024408A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to pharmaceutical compositions of cannabinoid agonists for application to the skin and the use thereof for preventing or minimizing the risk of cannabinoid agonist abuse and/or cannabinoid agonist toxicity from either intentional or unintentional tampering. The present invention is also directed at a method of preventing or minimizing the risk of cannabinoid agonist abuse and/or cannabinoid agonist toxicity from either intentional or unintentional tampering.
PCT/US2007/018585 2006-08-22 2007-08-22 Pharmaceutical formulations of cannabinoids for application to the skin and method of use WO2008024408A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US83911506P 2006-08-22 2006-08-22
US83911706P 2006-08-22 2006-08-22
US60/839,115 2006-08-22
US60/839,117 2006-08-22
US84097106P 2006-08-30 2006-08-30
US84096906P 2006-08-30 2006-08-30
US60/840,969 2006-08-30
US60/840,971 2006-08-30

Publications (2)

Publication Number Publication Date
WO2008024408A2 WO2008024408A2 (en) 2008-02-28
WO2008024408A3 true WO2008024408A3 (en) 2008-10-23

Family

ID=39107387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018585 WO2008024408A2 (en) 2006-08-22 2007-08-22 Pharmaceutical formulations of cannabinoids for application to the skin and method of use

Country Status (1)

Country Link
WO (1) WO2008024408A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2010056309A2 (en) * 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
DE102009036485B4 (en) * 2009-08-07 2012-10-04 Lts Lohmann Therapie-Systeme Ag Agent for the destructive disposal of medical active substances in transdermal therapeutic systems
EP3834869A1 (en) 2010-12-22 2021-06-16 Syqe Medical Ltd. System for drug delivery
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst Compositions and methods for treatment of symptoms in parkinson's disease patients
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
RU2700926C2 (en) * 2014-01-22 2019-09-24 4П Терапьютикс Transdermal systems preventing abuse and misuse
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
ES2898173T3 (en) 2014-06-30 2022-03-04 Syqe Medical Ltd Devices and systems for the pulmonary administration of active ingredients
IL273507B1 (en) 2014-06-30 2024-02-01 Syqe Medical Ltd Methods, devices and systems for pulmonary delivery of active agents
DK3160558T3 (en) 2014-06-30 2020-04-27 Syqe Medical Ltd FLOW CONTROL INHALING DEVICE
CA2953074C (en) 2014-06-30 2024-01-02 Syqe Medical Ltd. Drug dose cartridge for an inhaler device
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
PL3160553T3 (en) 2014-06-30 2022-02-21 Syqe Medical Ltd. Device for vaporization and inhalation of isolated substances
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
JP2018511355A (en) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Drug delivery method and system
WO2016133824A1 (en) * 2015-02-16 2016-08-25 Axim Biotechnologies, Inc. Cosmetic and topical compositions comprising cannabigerol
BR112017018316A2 (en) 2015-02-27 2018-04-17 Ebbu Llc compositions comprising combinations of purified cannabinoids with at least one flavonoid, terpene or mineral
CN107427472B (en) * 2015-03-02 2021-04-30 久光制药株式会社 Adhesive patch
EP3267875A4 (en) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Craving input and support system
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US20170042791A1 (en) * 2015-08-11 2017-02-16 KannaInnovations LLC Topical compositions comprising hydroxy acids and cannabinoids for skin care
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
US11806331B2 (en) 2016-01-06 2023-11-07 Syqe Medical Ltd. Low dose therapeutic treatment
CA3016464A1 (en) 2016-03-08 2017-09-14 Soo-Young Kang Long lasting cosmetic compositions
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
MX2018012913A (en) 2016-04-22 2019-01-30 Receptor Life Sciences Inc Fast-acting plant-based medicinal compounds and nutritional supplements.
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
WO2018044953A1 (en) 2016-08-29 2018-03-08 Ebbu, LLC Water soluble compositions comprising purified cannabinoids
EA201892396A1 (en) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. QUICKLY PRODUCTIVE PLANT MEDICINES AND BIOLOGICALLY ACTIVE ADDITIVES
JP2020503950A (en) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Device and method for transdermal drug delivery
US20220323401A1 (en) * 2017-02-15 2022-10-13 Botanix Pharmaceuticals Ltd. Formulations of cannabinoids for the treatment of acne
WO2018148785A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
EP3582769A4 (en) * 2017-02-15 2020-11-18 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of psoriasis
WO2018148786A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of acne
WO2018148787A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of psoriasis
EP3582768A4 (en) * 2017-02-15 2020-11-18 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
WO2018165078A1 (en) * 2017-03-06 2018-09-13 Korbutov Jack D Cannabinoid-containing dermatological compositions and methods using same
JP6801554B2 (en) * 2017-03-29 2020-12-16 東洋インキＳｃホールディングス株式会社 A method for manufacturing a skin adhesive, a skin adhesive, and a skin adhesive with a peeling sheet-like member.
CN106943235A (en) * 2017-03-31 2017-07-14 南阳医学高等专科学校 Belly protective belt after a kind of caesarean section
CN111065665B (en) 2017-09-13 2023-03-17 生活实验公司 Color protectant compositions
CA3074843A1 (en) 2017-09-13 2019-03-21 Living Proof, Inc. Long lasting cosmetic compositions
CN111801093A (en) * 2017-10-17 2020-10-20 雷米生物科学公司 Improved delivery systems for moieties including CBD-enhanced compositions, formulations, and chimeras
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
CN107997882A (en) * 2017-12-07 2018-05-08 云南汉木森生物科技有限责任公司 A kind of sanitary napkin with antibacterial anti-inflammatory, analgesic efficacy and preparation method thereof
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
CN111936126A (en) 2018-01-24 2020-11-13 博塔尼克斯制药有限公司 Cannabinoid dosing regimens for dermatitis and inflammatory skin disorders
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10980772B2 (en) * 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020183350A1 (en) * 2019-03-12 2020-09-17 Radient Technologies Innovations Inc. Transdermal patch kit with transdermal dosage units
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11355822B2 (en) * 2020-01-23 2022-06-07 Duracell U.S. Operations, Inc. Battery peel off assembly for exposing a safety feature comprising an aversive agent
WO2022046961A1 (en) * 2020-08-26 2022-03-03 Babak Ghalili Cannabinoid and menthol transdermal delivery systems and methods
US11141404B1 (en) * 2020-11-18 2021-10-12 Anebulo Pharmaceuticals, Inc. Formulations and methods for treating acute cannabinoid overdose
CN113384558A (en) * 2021-02-01 2021-09-14 深圳普洛美康材料有限公司 Transdermal patch for delivering cannabis active substance
US11795146B2 (en) 2021-10-11 2023-10-24 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
US20030125659A1 (en) * 2000-05-25 2003-07-03 Wolfgang Fleischer Dosage of transdermal delivery systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125659A1 (en) * 2000-05-25 2003-07-03 Wolfgang Fleischer Dosage of transdermal delivery systems
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy

Also Published As

Publication number Publication date
WO2008024408A2 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2008024408A3 (en) Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2008021394A3 (en) Pharmaceutical formulations of cannabinoids and method of use
WO2008027442A3 (en) Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
WO2008024490A3 (en) Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
WO2007087452A3 (en) Abuse resistant and extended release formulations and method of use thereof
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008013838A3 (en) Pyridizinone derivatives
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007136439A3 (en) Hyperpolarization methods, systems and compositions
WO2007077560A3 (en) Cryoprotective compositions and methods of using same
WO2008010921A3 (en) Modulators of pharmacokinetic properties of therapeutics
CL2008000507A1 (en) REGAPESPECIFIC PREPARATION OF 42-ESTER OF RAPAMYCIN WITH 3-HYDROXY-2- ACID (HYDROXY METHYL) -2- PROPIONIC METAL, PROTECTED WITH ISOPROPILIDENCETAL; AND PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND.
MY148496A (en) Dpp iv inhibitor formulations
WO2007109604A3 (en) Pharmaceutical compositions
WO2007095043A3 (en) Pharmaceutical formulations
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008112164A3 (en) Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006129318A3 (en) Benzofuran derivatives with therapeutic activities
WO2008105383A1 (en) Pyrazole derivative and use thereof for medical purposes
WO2004009091A8 (en) Purine derivatives as liver x receptor agonists
WO2007109523A3 (en) Stabilized ophthalmic compositions comprising oxidatively unstable components

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837213

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07837213

Country of ref document: EP

Kind code of ref document: A2